(secondQuint)Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B.

 LB80380, an oral prodrug, is a promising candidate nucleotide analogue with antiviral activity against wild-type HBV.

 LB80380 is undergoing clinical development by LG Life Sciences for use in the treatment of chronic HBV infection.

 In this study, the treatment period is 48-week with 24-week of follow-up period.

.

 Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B@highlight

The purpose of the study is to investigate the safety and the antiviral activity of two doses of LB80380 for 48 weeks in treatment-naive patients with chronic hepatitis B infection compared to entecavir 0.

5 mg.

